Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer
Jia Wang, Fengling Wang, Qiang Zhou, Yue Huang, Mengjun Yu, Shiwen Chen, Jing Gong, Min Yang, Qiang He, Jingbin Huang, Yu Zhao · 2026
Read Co-delivery of endoplasmic reticulum-targeted photosensitizer and Ido-1 inhibitor potentiates immunotherapeutic efficacy in triple-negative breast cancer by Jia Wang, Fengling Wang, Qiang Zhou, Yue Huang, Mengjun Yu, Shiwen Chen, Jing Gong, Min Yang, Qiang He, Jingbin Huang, Yu Zhao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13241888.txt.
Description
Jia Wang and a large team report a 2026 nanoparticle study for triple-negative breast cancer, a type that responds poorly to immunotherapy. Their particle carries two agents: a light-activated drug that targets the cell protein-folding compartment, and an inhibitor of an enzyme tumors use to dodge immunity.
The carrier homes to tumors through a targeting peptide. Light triggers the first drug to produce reactive oxygen inside the target compartment, killing cells in a way that alerts the immune system. The second drug blocks a metabolic escape route at the same time. In mice, tumors shrank sharply, killer T cell entry rose, and suppressive cells fell, with no visible whole-body toxicity. The authors propose the pairing as a durable immunity strategy.
Catalog record
| CREATOR | Jia Wang, Fengling Wang, Qiang Zhou, Yue Huang, Mengjun Yu, Shiwen Chen, Jing Gong, Min Yang, Qiang He, Jingbin Huang, Yu Zhao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 45 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |